Gilead Reports One-Year Results of Lenacapavir in P-II/III (CAPELLA) & P-II (CALIBRATE) Trial for the Treatment of HIV
- The P-II/III (CAPELLA) trial evaluates lenacapavir (q6mos., SC) + antiretroviral agents vs PBO in a ratio (2:1) in 36 patients with HIV. The company presented additional data of lenacapavir + F/TAF in the P-II (CALIBRATE) trial
- The 1yr. results from both trials showed that patients achieved high rates of virologic suppression & increases in CD4, 83% & 90% of patients achieved an undetectable viral load (<50 copies/mL) @52wk. while viral load reduction from baseline of 0.5 log10 copies/mL for 14 days functional monothx. period (88% vs 17%) in (CAPELLA) trial
- The therapy was well tolerated with no drug-related SAEs, The results support the development of lenacapavir with other agents for HIV-1
Ref: Businesswire | Image: Gilead
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].